Day One Cash Per Share vs. Current Valuation

DAWN Stock  USD 13.42  0.30  2.19%   
Based on the measurements of profitability obtained from Day One's financial statements, Day One Biopharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Day One's ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
4.59236811
Current Value
2.49
Quarterly Volatility
1.80884945
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Day One's Tangible Book Value Per Share is very stable compared to the past year. As of the 25th of November 2024, Graham Number is likely to grow to 15.97, though Free Cash Flow Yield is likely to grow to (0.12).
For Day One profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Day One to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Day One Biopharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Day One's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Day One Biopharmaceuticals over time as well as its relative position and ranking within its peers.
  

Day One's Revenue Breakdown by Earning Segment

Check out Investing Opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Day One Biopharmaceu Current Valuation vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Day One's current stock value. Our valuation model uses many indicators to compare Day One value to that of its competitors to determine the firm's financial worth.
Day One Biopharmaceuticals is rated # 2 in cash per share category among its peers. It is rated as one of the top companies in current valuation category among its peers reporting about  153,874,192  of Current Valuation per Cash Per Share. At this time, Day One's Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Day One's earnings, one of the primary drivers of an investment's value.

Day Current Valuation vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Day One

Cash Per Share

 = 

Total Cash

Average Shares

 = 
5.38 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Day One

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
827.84 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Day Current Valuation vs Competition

Day One Biopharmaceuticals is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.38 Billion. Day One totals roughly 827.84 Million in current valuation claiming about 60% of equities under Health Care industry.

Day One Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Day One, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Day One will eventually generate negative long term returns. The profitability progress is the general direction of Day One's change in net profit over the period of time. It can combine multiple indicators of Day One, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeK9.4 K
Net Interest Income5.5 M5.7 M
Operating Income-206.1 M-195.8 M
Net Loss-188.9 M-179.5 M
Income Before Tax-188.9 M-179.5 M
Total Other Income Expense Net17.1 M18 M
Net Loss-128 M-134.4 M
Net Loss-188.9 M-179.5 M
Income Tax Expense-9 M-8.6 M
Interest Income4.3 M4.1 M
Non Operating Income Net Other-13.5 K-14.2 K
Change To Netincome31.3 M20.8 M
Net Loss(2.37)(2.49)
Income Quality 0.78  0.45 
Net Income Per E B T 0.84  0.74 

Day Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Day One. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Day One position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Day One's important profitability drivers and their relationship over time.

Use Day One in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Day One Pair Trading

Day One Biopharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Day One position

In addition to having Day One in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Gold and Gold Mining Thematic Idea Now

Gold and Gold Mining
Gold and Gold Mining Theme
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out Investing Opportunities.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
To fully project Day One's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Day One Biopharmaceu at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Day One's income statement, its balance sheet, and the statement of cash flows.
Potential Day One investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Day One investors may work on each financial statement separately, they are all related. The changes in Day One's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Day One's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.